We plan to invest approximately $6.5 billion in production, compared to investments of approximately $3.6 billion last year." According to healthcare analysts Trilliant Health, requests for Ozempic and other semaglutides rose by 300 percent across the U.S
The Trump administration has promoted Most-Favored Nation pricing initiatives aimed at preventing Americans from paying more than patients overseas, but the policies have faced legal challenges
The ones waiting for the trend to become undeniable are ceding that window, and Circanas analysis adds a further layer of urgency: the categories with the steepest GLP-1 spending declines are often the same categories with the most bloated SKU counts, the result of years of incremental product extensions that made sense when volume was growing but become expensive to maintain as demand contracts
It is not approved for human consumption, therapeutic use, or veterinary application
Effects in PCOS GLP-1 RAs have been extensively studied in women with PCOS due to overlapping metabolic abnormalities